吉非替尼对比培美曲塞联合顺铂治疗术后EGFR突变阳性Ⅱ~ⅢA期肺腺癌的临床分析
Clinical analysis of gefitinib versus pemetrexed combined with cisplatin in patients with stage Ⅱ-ⅢA lung adenocarcinoma harbouring positive EGFR mutations

DOI: 10.6040/j.issn.1671-7554.0.2018.419

Keywords: 肺腺癌,表皮生长因子受体突变,培美曲塞,辅助化疗,吉非替尼,
Lung adenocarcinoma,Pemetrexed,Adjuvant chemotherapy,Gefitinib,Epidermal growth factor receptor mutation

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(4): 504-535.
[2]	Mountain CF. Revisions in the international system for staging lung cancer[J]. Chest, 1997, 111(6): 1710-1717.
[3]	Zhi XY, Yu JM, Shi YK. Chinese guidelines on the diagnosis and treatment of primary lung cancer(2015 version)[J]. Cancer, 2016, 121(suppl 17): 3165-3181.
[4]	Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. N Engl J Med, 2010, 362(25): 2380-2388.
[5]	Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor(WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(2): 121-128.
[6]	Kreuter M, Vansteenkiste J, Fischer JR, et al. Three-year follow-up of a randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine(the TREAT study)[J]. J Thorac Oncol, 2016, 11(1): 85-93.
[7]	Goss GD, OCallaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study[J]. J Clin Oncol, 2013, 31(27): 3320-3326.
[8]	Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant erlotinib versus placebo in patients with stage ⅠB-ⅢA non-small-cell lung cancer(RADIANT): a randomized, double-blind, phase Ⅲ trial[J]. J Clin Oncol, 2015, 33(34): 4007-4014.
[9]	Lv C, An C, Feng Q, et al. A retrospective study of stage I to IIIa lung adenocarcinoma after resection: what is the optimal adjuvant modality for patients with an EGFR mutation?[J] Clin Lung Cancer, 2015, 16(6): e173-e181. doi: 10.1016/j.cllc.2015.04.002.
[10]	Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage Ⅱ-ⅢA(N1-N2)EGFR-mutant NSCLC(ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2017, 19(1): 139-148.
[11]	Janjigian YY, Park BJ, Zakowski MF, et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations[J]. J Thorac Oncol, 2011, 6(3): 569-575.
[12]	Takahashi K.[Lung cancer: progress in diagnosis and treatments. Topics: Ⅲ. Treatment; 3. Chemotherapy for patients with non-small cell lung cancer, 1)Cytotoxic drug treatment, maintenance therapy, and secondary line treatment] [J]. Nihon Naika Gakkai Zasshi, 2014, 103(6): 1306-1313.
[13]	Kris MG, Gaspar LE, Chaft JE, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage Ⅰ to ⅢA completely resected non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline update[J]. J Clin Oncol, 2017, 35(25): 2960-2974.
[14]	Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, version 4.2016[J]. J Natl Compr Canc Netw, 2016, 14(3): 255-264.
[15]	Zhai X, Zheng Q, Yang L, et al. Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma[J]. Sci Rep, 2017, 7(1): 1453. doi: 10.1038/s41598-017-01347-6.
[16]	Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10): 947-957.
[17]	Ding PN, Lord SJ, Gebski V, et al. Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a Meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR-mutated non-small cell lung cancer[J]. J Thorac Oncol, 2017, 12(4): 633-643.
[18]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012 [J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[19]	Eberhardt WE, De Ruysscher D, Weder W, et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer[J]. Ann Oncol, 2015, 26(8): 1573-1588.
[20]	Schmid-Bindert G, Engel-Riedel W, Reck M, et al. A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage ⅠB or Ⅱ Non-Small-Cell Lung Cancer[J]. Lung Cancer, 2015, 90(3): 397-404.
[21]	Karapanagiotou EM, Boura PG, Papamichalis G, et al. Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer(NSCLC): a phase II study[J]. Anticancer Res, 2009, 29(10): 4297-4301.
[22]	Kang CH, Ra YJ, Kim YT, et al. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer[J]. Ann Thorac Surg, 2008, 86(4): 1092-1097.
[23]	Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib[J]. J Clin Oncol, 2006, 24(16): 2549-2556.
[24]	Kudoh S, Kato H, Nishiwaki Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study[J]. Am J Respir Crit Care Med, 2008, 177(12): 1348-1357.
[25]	Shi L, Tang J, Tong L, et al. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials[J]. Lung Cancer, 2014, 83(2): 231-239.

Full-Text